Fortress Biotech, Inc.

FBIO

US34960Q3074

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 22/05/2024 BST			5-day change	1st Jan Change
1.87 ^USD	-5.56%		+7.47%	-37.87%

05-15	Earnings Flash (FBIO) FORTRESS BIOTECH Posts Q1 Revenue $13M	MT
05-14	Fortress Biotech Says First Patient Dosed in Phase 2 Study of Triplex	MT

Coronado Biosciences, Inc. to Appoint Hehenberger Coronado as Executive Vice President of Scientific Affairs

August 05, 2013 at 12:32 pm

Effective August 1, 2013, Coronado and Dr. Hehenberger entered into an Amendment to Employment Agreement to appoint Dr. Hehenberger Coronado's Executive Vice President of Scientific Affairs. Dr. Hehenberger previously served as Coronado's Executive Vice President and Chief Medical Officer, from April 19, 2012 to July 31, 2013.

Latest news about Fortress Biotech, Inc.

Earnings Flash (FBIO) FORTRESS BIOTECH Posts Q1 Revenue $13M	05-15	MT
Fortress Biotech Says First Patient Dosed in Phase 2 Study of Triplex	05-14	MT
Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation	05-14	CI
North American Morning Briefing : Powell Awaited -2-	04-03	DJ
Certain Warrants of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 2-APR-2024.	04-01	CI
Certain Options of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 2-APR-2024.	04-01	CI
Certain Common Stock of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 2-APR-2024.	04-01	CI
Fortress Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Alliance Global Partners Initiates Fortress Biotech at Buy Rating With $5 Price Target	03-19	MT
Certain Preferred Stock of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 8-FEB-2024.	02-07	CI
Certain Common Stock of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 8-FEB-2024.	02-07	CI
Eric Rowinsky Announces Not Stand for Re-Election to the Board of Fortress Biotech, Inc	01-26	CI
Fortress Biotech Prices $11 Million Offering of Stock, Warrants; Shares Sink in Early Trading	12-29	MT
Roth MKM Lowers Price Target on Fortress Biotech to $15 From $30, Maintains Buy Rating	11-29	MT
Top Midday Gainers	11-17	MT
Fortress Biotech Insider Bought Shares Worth $2,664,776, According to a Recent SEC Filing	11-16	MT
Fortress Biotech Insider Bought Shares Worth $249,999, According to a Recent SEC Filing	11-16	MT
Earnings Flash (FBIO) FORTRESS BIOTECH Posts Q3 Revenue $34.8M	11-14	MT
Fortress Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Wall Street Set to Open Slightly Higher as Investors Parse Powell Remarks	11-10	MT
Top Premarket Decliners	11-10	MT
Fortress Biotech Begins Public Offering of Units	11-10	MT
Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 Mg) Vs. Solodyn (Minocycline Hydrochine Hydrochloride Extended-Release Tablets, 105 Mg)	20/10/23	CI
Fortress Biotech Announces 1-for-15 Reverse Stock Split	09/10/23	MT
Avenue Therapeutics, Inc. announced that it expects to receive $0.55 million in funding from Fortress Biotech, Inc. and other investor	07/09/23	CI

Chart Fortress Biotech, Inc.

Duration

Period

More charts

Company Profile

Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has seven marketed prescription pharmaceutical products and over 25 programs in development at the Company, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Such product candidates span six market areas, including oncology, rare diseases and gene therapy. Its dermatology products include Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Exelderm and Luxamend. Its late stage product candidates include Cosibelimab (anti-PD-L1 antibody), DFD-29 (modified release oral minocycline for the treatment of rosacea), CUTX-101 (copper histidinate injection for Menkes disease), IV Tramadol, Olafertinib (also known as CK-101, EGFR inhibitor for EGFR mutation-positive NSCLC), CAEL-101 (monoclonal antibody for AL amyloidosis) and Triplex (cytomegalovirus (CMV) vaccine).

Sector

Pharmaceuticals

Calendar

03:00pm - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Fortress Biotech, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.87 USD

Average target price

10.75 USD

Spread / Average Target

+474.87%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
FORTRESS BIOTECH, INC.	-37.87%	37.24M
CSL LIMITED	-1.62%	89.22B
SAMSUNG BIOLOGICS CO.,LTD.	+2.24%	40.49B
BIOGEN INC.	-12.97%	32.79B
UCB	+63.56%	26.23B
BIOMARIN PHARMACEUTICAL INC.	-20.71%	14.52B
INCYTE CORPORATION	-7.31%	13.09B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.64%	11.5B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.60%	11.6B
SWEDISH ORPHAN BIOVITRUM AB	+5.47%	8.82B

Biopharmaceuticals

Fortress Biotech, Inc.

Equities

FBIO

US34960Q3074

Pharmaceuticals

Coronado Biosciences, Inc. to Appoint Hehenberger Coronado as Executive Vice President of Scientific Affairs

EPS Revisions